Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in RRMM

Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA
Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in RRMM ( Dr Doris Hansen - Moffitt Cancer Center, Tampa, USA )
17 Dec 2024

Bispecific antibody therapy for lymphoma patients failing CAR T-Cell therapy

Dr Matthew Matasar - Rutgers Cancer Institute, New Jersey, USA
Bispecific antibody therapy for lymphoma patients failing CAR T-Cell therapy ( Dr Matthew Matasar - Rutgers Cancer Institute, New Jersey, USA )
17 Dec 2024

Teclistamab-based induction regimens demonstrate manageable safety and efficacy in patients with transplant-eligible NDMM

Prof Marc Raab - Heidelberg Myeloma Center, Heidelberg, Germany
Teclistamab-based induction regimens demonstrate manageable safety and efficacy in patients with transplant-eligible NDMM ( Prof Marc Raab - Heidelberg Myeloma Center, Heidelberg, Germany )
17 Dec 2024

Addition of tafasitamab to lenalidomide plus rituximab significantly improves efficacy in R/R follicular lymphoma

Dr Christina Poh - Fred Hutchinson Cancer Centre, Seattle, USA
Addition of tafasitamab to lenalidomide plus rituximab significantly improves efficacy in R/R follicular lymphoma ( Dr Christina Poh - Fred Hutchinson Cancer Centre, Seattle, USA )
17 Dec 2024

Pembrolizumab shows improvement in overall survival for clear cell renal cell carcinoma

Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany
Pembrolizumab shows improvement in overall survival for clear cell renal cell carcinoma ( Prof Jens Bedke - Klinikum Stuttgart-Katharinenhospital, Stuttgart, Germany )
17 Dec 2024

Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC

Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Irradiation plus ADT with GnRH antagonist vs. GnRH agonist shows similar efficacy in high risk locally advanced PC ( Dr Thomas Zilli - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )
17 Dec 2024

Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL

Dr Rachel Rau - University of Washington, Seattle, USA
Blinatumomab added to chemotherapy improves disease-free survival in newly diagnosed NCI standard risk paediatric B-ALL ( Dr Rachel Rau - University of Washington, Seattle, USA )
16 Dec 2024

Outcomes and survival in newly diagnosed, older, AML patients from the Beat AML master trial in the venetoclax/azacitidine age

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA
Outcomes and survival in newly diagnosed, older, AML patients from the Beat AML master trial in the venetoclax/azacitidine age ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )
16 Dec 2024

IDH2 mutation associated with favourable outcome in older adults with newly diagnosed ALL treated with lower-intensity therapy

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA
IDH2 mutation associated with favourable outcome in older adults with newly diagnosed ALL treated with lower-intensity therapy ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )
16 Dec 2024

Demographics, characteristics, survival and outcomes in older, untreated, AML with NPM1 mutations or KMT2A rearrangements

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA
Demographics, characteristics, survival and outcomes in older, untreated, AML with NPM1 mutations or KMT2A rearrangements ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )
16 Dec 2024

Beat AML master trial update: A clinical trial for acute myeloid leukaemia

Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA
Beat AML master trial update: A clinical trial for acute myeloid leukaemia ( Dr Ashley Yocum - Leukemia & Lymphoma Society, New York, USA )
16 Dec 2024

Impact of MRD on progression-free survival in MM patients treated with isatuximab, lenalidomide, bortezomib and dexamethasone

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany
Impact of MRD on progression-free survival in MM patients treated with isatuximab, lenalidomide, bortezomib and dexamethasone ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )
16 Dec 2024